AU7R-104 / Dr. Reddy’s - LARVOL DELTA

A Study of AUR104 in Patients with Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited

New P1 trial • Hematological Malignancies • Oncology

[VIRTUAL] Discovery and preclinical evaluation of a novel covalent inhibitor of FABP5 for cancer therapy (AACR 2021) - "In summary, we have identified a novel covalent FABP5 inhibitor with optimized properties that showed anti-tumor activity in in vitro and in vivo models with acceptable safety profile. The data presented here strongly support clinical development of AUR104."

Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FABP5 • IL10 • IL6 • MALT1